← Leaderboards
Terry Fry
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocytePreventBaseTumorLeukemiaPublishingRelapseAntigensBloodLeukemia, Lymphocytic, Acute, L1ReceptorDendritic CellsCd19 GeneMalignant NeoplasmsLaboratoriesImmunotherapeutic AgentImmuneClinical TrialsMediatingB-LymphocytesImmune SystemMalignant Childhood NeoplasmIn VivoCells
Grant awards (21)
Adoptive T cell Therapy for Pediatric Leukemia$771,137
ZIA · FY2018 · CA · contact PI
ALL immunobiology and the bone marrow niche$330,488
ZIA · FY2018 · CA · contact PI
Adoptive T cell Therapy for Pediatric Leukemia$1,080,868
ZIA · FY2017 · CA · contact PI
ALL immunobiology and the bone marrow niche$463,229
ZIA · FY2017 · CA · contact PI
Adoptive T cell Therapy for Pediatric Leukemia$1,511,241
ZIA · FY2016 · CA · contact PI
ALL immunobiology and the bone marrow niche$647,674
ZIA · FY2016 · CA · contact PI
Adoptive T cell Therapy for Pediatric Leukemia$985,195
ZIA · FY2015 · CA · contact PI
ALL immunobiology and the bone marrow niche$422,227
ZIA · FY2015 · CA · contact PI
Adoptive T cell Therapy for Pediatric Leukemia$879,682
ZIA · FY2014 · CA · contact PI
ALL immunobiology and the bone marrow niche$377,007
ZIA · FY2014 · CA · contact PI
Optimizing the graft versus leukemia effect for pediatric ALL$942,362
ZIA · FY2013 · CA · contact PI
Targeting dendritic cells for selective modulation of Graft-versus-Host Disease$166,299
ZIA · FY2013 · CA · contact PI
Optimizing the graft versus leukemia effect for pediatric ALL$846,887
ZIA · FY2012 · CA · contact PI
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants$260,581
ZIA · FY2012 · CA · contact PI
Targeting dendritic cells for selective modulation of Graft-versus-Host Disease$195,436
ZIA · FY2012 · CA · contact PI
Optimizing the graft versus leukemia effect for pediatric ALL$414,815
ZIA · FY2011 · CA · contact PI
Targeting dendritic cells for selective modulation of GVHD$248,889
ZIA · FY2011 · CA · contact PI
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants$165,926
ZIA · FY2011 · CA · contact PI
Optimizing the graft versus leukemia effect for pediatric ALL$330,006
ZIA · FY2010 · CA · contact PI
Targeting dendritic cells for selective modulation of GVHD$198,004
ZIA · FY2010 · CA · contact PI
Development of dipeptidyl peptidase inhibitors as novel immune adjuvants$132,002
ZIA · FY2010 · CA · contact PI